BioSpace News Archive

Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders, today announced the provisional acceptance and early online publication of a peer-reviewed article authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun, M.D., Ph.D.,

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has set November 5, 2020 as the record date for its previously-announced proposed rights offering of up to $15 million of shares of its common stock and the expected subscription period.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent business highlights.

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to discuss the company’s third quarter 2020 financial results

-- GFB-887, a first-in-class highly potent and selective inhibitor of the TRPC5-Rac1 pathway, was well-tolerated in single ascending doses -- -- GFB-887 induced dose-dependent reductions in urinary Rac1, demonstrating target engagement -- -- TRPC5-Rac1 pathway overactivation is key cause of disease in substantial portion of patients with focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN) --

Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its third quarter ended September 30, 2020 after the market closes on Thursday, October 29, 2020.

Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM

Terns Pharmaceuticals, Inc. announced the presentation of new clinical data on an improved tablet formulation of its liver-distributed farnesoid X receptor agonist TERN-101 at the Paris NASH Digital Experience, taking place virtually October 22-23, 2020.

IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced important commercial milestones from the launch of its IRRAflow system in Germany.

Mesoblast Limited announced that a randomized, controlled study of remestemcel-L delivered by an endoscope directly to the areas of inflammation and tissue injury in up to 48 patients with medically refractory Crohn’s disease and ulcerative colitis has commenced at Cleveland Clinic.